

# Naturally occurring mutations and functional polymorphisms in multidrug resistance 1 gene: correlation with microsatellite instability and lymphoid infiltration in colorectal cancers

U Potočnik, M Ravnik-Glavač, R Golouh, D Glavač

*J Med Genet* 2002;**39**:340–346

**P**glycoprotein (Pgp), encoded by the *MDR1* gene, is a transmembrane transporter that acts as an efflux pump in an ATP dependent fashion.<sup>1</sup> Multidrug resistance, the main problem in efficient cancer chemotherapy, is mainly caused by increased expression and acquired mutations in the *MDR1* gene.<sup>2</sup> Pgp is expressed physiologically in epithelial cells of the kidney, liver, pancreas, and colon, suggesting its role in secretion of toxic compounds.<sup>3</sup> Pgp is also expressed in the blood-brain barrier, adrenal glands, and lymphocytes where its role is still uncertain. Recently, additional functions for Pgp, including immune response<sup>4</sup> and regulation of apoptosis,<sup>5</sup> have been suggested in normal tissues and in cancers. High expression of Pgp at the apical surface of differentiated tubular structures was identified in previously untreated colorectal cancers (CRC)<sup>6</sup> and its high expression at the leading edge of a colorectal carcinoma was associated with tumour progression.<sup>7</sup>

In contrast to the majority of CRC, which develop as a result of chromosomal instability (CIN), a proportion of sporadic CRC and 90% of cancers in patients with hereditary non-polyposis colorectal cancer (HNPCC) exhibit microsatellite instability (MSI).<sup>8</sup> In MSI CRC, chromosomal aberrations such as large deletions, translocations, and gene amplifications are rare; the great majority of MSI tumours are usually diploid or near diploid. In MSI CRC, inactivation of the mismatch repair (MMR) system owing to mutations or methylation of MMR genes results in a 1000-fold accumulation of point mutations in oncogenes and tumour suppressor genes which trigger tumour progression. Therefore, in addition to genes mutated in microsatellite stable (MSS) CRC, such as *APC*, *p53*, and *K-ras*, there are other genes important in the development of MSI cancers. Interestingly, MSI CRCs are also more often resistant to several chemotherapy drugs; the selection of cells for resistance to cisplatin can result in the loss of DNA mismatch repair, and loss of DNA mismatch repair in turn contributes to resistance to cisplatin.<sup>9</sup> Recently, a transcription factor complex TCF4/β catenin responsive element was identified in the *MDR1* promoter region pointing to a direct link between the *MDR1* gene and the WNT signalling pathway, the most important pathway altered in colorectal cancers.<sup>10</sup> To determine the role of the *MDR1* gene in the initiation and progression of CRC, we systematically screened the complete coding and promoter region of the *MDR1* gene for alterations in a large cohort of patients with previously untreated colorectal cancer and in a normal control population. In this study, we report naturally occurring functional germline and somatic mutations in the *MDR1* gene in patients with microsatellite unstable CRC and correlation of *MDR1* functional polymorphisms with increased lymphoid infiltration in tumours with and without MSI.

## MATERIALS AND METHODS

### Patients

Between 1996 and 2000, 400 newly diagnosed colorectal cancer (CRC) patients from clinics all over Slovenia participated in this study. None of these patients had received chemotherapy treatment before operation. Primary colorectal adenocarcinomas as well as corresponding normal colorectal mucosa taken from a site several centimetres distant from the tumour were used in the study. Tumours were histopathologically evaluated according to the classification of Jass *et al.*<sup>11</sup> The lymphoid infiltration of the tumours was assessed semiquantitatively by two independent pathologists. Accordingly, tumours with well represented lymphocytes along the advancing margin of the tumour were scored as positive for lymphoid infiltration.

### Control samples

To determine the potential pathogenicity of *MDR1* alterations detected in our study, we also analysed DNA from 100 unrelated unaffected blood donors.

### DNA isolation

Colorectal tumours and corresponding normal tissue samples were snap frozen in liquid nitrogen and stored at  $-70^{\circ}\text{C}$ . DNA was isolated after tissue digestion using standard phenol/chloroform extraction and ethanol precipitation.


### Analysis of microsatellite instability

Microsatellite instability (MSI) analysis using a "reference panel" of microsatellite markers was performed in 400 unselected primary colorectal cancers (CRC) as described in our previous study.<sup>12</sup> Thirty-eight tumours were defined as high microsatellite instability tumours (MSI-H) and analysed for *MDR1* mutations.

### *MDR1* mutational analysis

We designed primers based on known genomic DNA sequences (Genbank accession numbers AC002457 and AC005068) specifically to amplify all 28 exons and exon/intron boundaries as well as the promoter region of the *MDR1* gene in separate PCR reactions. Primer sequences and optimised PCR conditions are available at uros.potocnik@mf.uni-lj.si. For mutational analysis of the *MDR1* gene, we used non-isotopic conformation analysis and silver staining. The basic principle of this method is a combination of three analyses which are all based on changes in


**Abbreviations:** Pgp, P glycoprotein; CRC, colorectal cancer; CIN, chromosome instability; HNPCC, hereditary non-polyposis colorectal cancer; MSI, microsatellite instability; MMR, mismatch repair; MSS, microsatellite stable; SSCA, single strand conformation analysis; HA heteroduplex analysis; DSCA, double strand conformation analysis



**Figure 1** Immunohistochemical staining for P glycoprotein using JSB-1 monoclonal antibodies. We observed moderate to high (A) and in some samples low (B) Pgp staining in epithelial cells of normal colonic mucosa. High Pgp staining was present in lymphocytes of normal mucosa, in particular in those forming lymphoid follicles (C, D, E). Even higher intensity of Pgp staining was observed in tumours compared to normal mucosa (F). In some tumour samples, high Pgp staining was present in lymphocytes of the infiltrating tumour border (G). The intensity of Pgp staining in tumours correlated with grading of tumours, being most intense in well differentiated (H), moderate in moderately differentiated (I), and low in poorly differentiated tumours (J).

three dimensional DNA structures, that is, single strand conformation analysis (SSCA), heteroduplex analysis (HA), and double strand conformation analysis (DSCA). We conducted them simultaneously on the same thin polyacrylamide gel. With this

method, more than 95% of point mutations could be identified.<sup>13</sup> Sequencing was performed with the BigDye Terminator Cycle Sequencing Ready Reaction Kit and ABI 310 sequencer (Perkin Elmer Cetus, Norwalk, CT, USA).



**Figure 2** Sequence analysis of the *MDR1* gene. (A) Germline mutation in exon 28 of the *MDR1* gene identified in tumour sample MSI 11. Arrow indicates G>A substitution at position 3793 resulting in an amino acid change at position 1265 from non-polar glycine to polar serine (G1265S). (B) Somatic mutation in the *MDR1* gene promoter region (-14 G>T) identified in tumour sample MSI 11. Arrow indicates C>A substitution (sequenced with reversed primer) 14 bp before the major transcription initiation site (numbering according to Kohno *et al*<sup>9</sup> (MSI 11 (tumour))). Sequencing of the *MDR1* promoter region in normal tissue from the same patient showed the somatic origin of this mutation (MSI 11 (normal)).

**Table 1** Mutations and germline promoter functional polymorphism in the *MDR1* gene identified in colorectal cancers with microsatellite instability

Sample	Origin	Exon	Nucleotide change	Consequence	Amino acid change	Domain	Consensus
MSI 3	Germline Somatic	Promoter 25	+8 T>C* 3149 T>C	I1050T	Non-polar>polar	IC6	Yes
MSI 5	Germline Somatic	Promoter 4	+8 T>C* 209 T>C	L70P	Non-polar>non-polar	TM1	Yes
MSI 11	Somatic Germline	Promoter 28	-14 G>T 3793 G>A	G1265S	Non-polar>polar	IC6	Yes
MSI 19	Somatic Somatic	Promoter 20	-29 G>A 2422-2426 del A	Frameshift		IC4	
MSI 22	Germline	Promoter	+8 T>C*				
MSI 34	Germline	8	729 A>G	E243 no change	/	/	/

IC=intracellular domain, TM=transmembrane domain.

\*This polymorphism was also identified in microsatellite stable tumours and in controls. Nucleotide numbering according to Kohno *et al.*[19]

### Methylation analysis

Tumour DNA was treated with sodium bisulphite to selectively convert only unmethylated cytosines in CpG sites of the *MDR1* promoter region to thymines as described previously.<sup>14</sup> To determine the methylation status of the *MDR1* promoter, sequencing of bisulphite modified DNA using previously reported primers was performed.<sup>15</sup> For sequencing we used the BigDye Terminator Cycle Sequencing Ready Reaction Kit and ABI 310 sequencer (Perkin Elmer Cetus, Norwalk, CT, USA). We scored a sample as hypermethylated if signals for unconverted methylated cytosines were higher than those for thymines converted from unmethylated cytosines in the majority of CpG sites after sequencing.

### Immunohistochemical analysis of P glycoprotein expression

Sections of formalin fixed and paraffin embedded tissue blocks of tumour and normal intestinal wall were used. In short, a mouse monoclonal antibody (JSB-1, Biogenex) at dilution 1:10 was applied after microwave antigen retrieval (citrate pH 6.0, 15 minutes, at 850 W). For detection of the antigen, the LSAB method, using DAKO Tech-mate stainer, and DAB were used. According to the intensity of the immunohistochemical staining estimated by two independent pathologists, samples were divided into three groups of low, moderate, and high Pgp expression. Samples with an estimated intensity of more than 50% (fig 1A, I) and less than 50% (fig 1J) of the most intensively stained sample were scored as high and moderate Pgp expression, respectively. Samples with no distinctive membrane staining (fig 1B, J) were scored as low Pgp expression. For statistical comparisons, moderate and high Pgp expression was evaluated against low Pgp expression.

### Statistical analysis

We used the  $\chi^2$  test with software package SPSS to compare clinicopathological characteristics between colorectal tumours with and without *MDR1* polymorphisms. We used the two sided Fisher exact test to compare *MDR1* mutations and methylation status with MSI status of colorectal tumours. We also used the two sided Fisher exact test to compare Pgp expression in unselected tumours (controls), tumours with functional polymorphisms, and MSI-H tumours. In all tests, p values of less than 0.05 were considered to indicate statistical significance.

## RESULTS

### Mutations and polymorphisms in the *MDR1* gene

We identified 12 different germline and five different somatic alterations in the *MDR1* gene in initial screening of 60 patients

with primary untreated colorectal cancer (CRC). Thirty patients with tumours exhibiting high microsatellite instability (MSI-H) and 30 patients with microsatellite stable (MSS) tumours were included in this initial screening. We confirmed the origin of the alterations by comparing DNA from tumour and from corresponding normal tissue. For exons with detected alterations, the study was extended to up to 350 patients with colorectal cancer and 100 unaffected blood donors. All alterations were identified as aberrant gel migration patterns with conformational analysis and further confirmed and characterised by direct sequencing of both DNA strands (forward, reverse) (fig 2). To exclude possible random errors, PCR and sequencing reactions were repeated at least three times for each alteration identified.

Seven different *MDR1* alterations, two germline and all five somatic, were only detected in 5/38 (13%) MSI-H tumours, but not in 400 patients with MSS tumours or in 100 controls ( $p < 0.001$ , table 1). In 4/5 MSI-H tumours with unique alterations in the coding region there were concomitant alterations in the promoter region ( $p < 0.001$ ). A unique missense germline alteration and all somatic coding region alterations identified in MSI-H tumours were in the codons conserved throughout the species. On the other hand, all missense germline alterations (table 2) identified in MSS CRC patients and in controls were in codons not conserved throughout the species. The germline G1265S substitution identified in sample MSI 11 was of special interest (fig 2). It was the only germline substitution in the coding region that was found in the MSI-H tumour with a concomitant somatic promoter mutation (fig 2). G1265S was also the only germline alteration that resulted in substitution of an amino acid conserved through species; in this case non-polar Gly is replaced by polar Ser. The G1265S substitution is located in the predicted IC12 domain after the ATP binding site. It was not found on 200 chromosomes from normal blood donors or on 800 chromosomes from patients with CRC.

In contrast to two germline alterations that we found only in MSI-H tumours, the frequency of 10 other detected germline alterations (table 2) did not differ between MSI-H, MSS CRC, and controls. Comparison of more frequent *MDR1* polymorphisms also identified in controls with clinicopathological data in patients with MSI-H and MSS CRC showed significant correlation between lymphoid infiltration in tumours and two polymorphisms, one in the promoter (+8 T>C,  $p = 0.036$ ) and the other in intron 1 (IVS1-81delG,  $p = 0.010$ ) (table 2). No significant correlation between *MDR1* polymorphisms and age, sex, tumour location, tumour type, Duke's stage, and differentiation grade was observed.

**Table 2** Correlation between *MDR1* polymorphisms and increased lymphoid infiltration in tumours

Exon	Genotype (polymorphism)	Amino acid change	No (%) of tumours with specific genotype (polymorphism)/No of tumours analysed	No (%) of tumours with specific genotype (polymorphism) and lymphoid infiltration	p*
Promoter	†Promoter +8 T/T		313/327 (96%)	152/313 (49%)	
Promoter	Promoter +8 T/C	Non-coding	14/327 (4%)	9/14 (64%)	0.036
Intron 1b	IVS1-81 (G) <sub>4</sub>		311/327 (95%)	149/311 (48%)	
Intron 1b	IVS1-81 (G) <sub>4</sub> /(G) <sub>3</sub>	Non-coding	16/327 (5%)	12/16 (75%)	0.010
Intron 1b	‡IVS-1 G/G		271/317 (85%)	127/271 (47%)	
Intron 1b	IVS-1 G/A		45/317 (14%)	27/45 (60%)	NS
Intron 1b	IVS-1 A/A	Non-coding	1/317 (<1%)	1/1 (100%)	NS
2	‡61 A/A		266/321 (83%)	125/266 (47%)	
2	61 A/G	Asn21Asp	51/321 (16%)	29/51 (57%)	NS
2	61 G/G		4/321 (1%)	2/4 (50%)	NS
Intron 4	‡IVS4-25 G/G		44/63 (70%)	19/44 (43%)	
Intron 4	IVS4-25 G/T	Non-coding	15/63 (24%)	7/15 (47%)	NS
Intron 4	IVS4-25 T/T		4/63 (6%)	2/4 (50%)	NS
11	1199 G/G		307/327 (94%)	152/307 (50%)	
11	1199 G/A	Ser400Asn	20/327 (6%)	11/20 (55%)	NS
12	‡1236 C/C		81/327 (25%)	39/81 (48%)	
12	1236 C/T	No change	163/327 (50%)	80/163 (49%)	NS
12	1236 T/T		83/327 (25%)	42/83 (51%)	NS
Intron 16	IVS16+158 G/G		82/87 (94%)	41/82 (50%)	
Intron 16	IVS16+158 G/A	Non-coding	5/87 (6%)	3/5 (60%)	NS
21	§2677 G/G		14/41 (34%)	7/14 (50%)	
21	2677 G/T	Ala893Ser	17/41 (41%)	7/17 (41%)	NS
21	2677 T/T		10/41 (24%)	4/10 (40%)	NS
26	‡3435 C/C		44/159 (28%)	18/44 (41%)	
26	3435 C/T	No change	85/159 (53%)	46/85 (54%)	NS
26	3435 T/T		30/159 (19%)	15/30 (50%)	NS

NS=not significant.  
 \*Using the  $\chi^2$  test, the proportions of tumours with lymphoid infiltration were compared among different alleles within the same locus (exon).  
 †Polymorphism previously described by Stein *et al.*<sup>20</sup>  
 ‡Polymorphism previously described by Hoffmeyer *et al.*<sup>21</sup>  
 §Polymorphism previously described by Mickley *et al.*<sup>22</sup>

### Methylation analysis of *MDR1* promoter

Genomic DNA from tumour and corresponding normal mucosa from 12 patients with MSI-H CRC and from 10 patients with microsatellite stable (MSS) CRC was analysed for *MDR1* promoter methylation. We observed hypermethylation of CpG sites in the *MDR1* promoter in tumour DNA from 10/12 (80%) of MSI-H tumours but in none of the 10 MSS tumours and corresponding normal mucosa ( $p < 0.001$ ). We observed hypermethylation of CpG sites in the whole *MDR1* promoter region analysed rather than associated with specific CpG sites.

### Pgp expression in colorectal tumours and corresponding normal mucosa

Colorectal tumours and corresponding normal mucosa from 14 colorectal cancer (CRC) patients with microsatellite stable tumours and without germline functional *MDR1* polymorphisms (control group), 28 CRC patients with functional germline *MDR1* polymorphisms, and 12 CRC patients with tumours exhibiting high microsatellite instability (MSI-H) were analysed for immunohistochemical Pgp expression (fig 1, table 3). For statistical comparisons, moderate and high Pgp expression was evaluated against low Pgp expression. We observed higher Pgp staining in cells from well and moderately differentiated tumours as compared to normal mucosa cells in all groups of CRC patients. Of 44 moderately and well differentiated tumours, 24 had high, 19 moderate, and one low Pgp expression while of 54 normal colon mucosa samples, 16 had high, 21 moderate, and 17 low Pgp expression

( $p = 0.005$ ). Intensity of Pgp staining in tumours correlated with grading of tumours, being most intense in well differentiated (10 tumours high and one tumour moderate Pgp expression), moderate in moderately differentiated (14 tumours high, 18 tumours moderate, and one tumour low Pgp expression), and low in poorly differentiated tumours (10 tumours low Pgp expression) ( $p < 0.0001$ ). In less differentiated tumours, Pgp expression was limited to the inner surface of the glands. We observed lower Pgp expression in MSI-H tumours as compared to tumours in the control group ( $p = 0.042$ ). Although not statistically significant, Pgp expression tended to be lower in epithelial cells of normal colon mucosa in CRC patients with functional *MDR1* polymorphisms and in CRC MSI-H patients as compared to the control group (table 3).

### DISCUSSION

In this study, we provide detailed and extensive analysis of germline and somatic alterations in the promoter and complete coding region of the *MDR1* gene in patients with previously untreated colorectal cancer (CRC) and in a normal control population. We have identified 12 different germline and five different somatic alterations. Of 10 different germline alterations identified in patients and controls, five were in non-coding regions, two did not change any amino acids, and three changed non-conserved amino acids. Two unique germline and all five somatic mutations were identified only in patients with colorectal cancers exhibiting high microsatellite instability (MSI-H, table 1). To the best of our knowledge, this

**Table 3** Immunohistochemical staining for P glycoprotein (Pgp)

Pgp expression	Control*		MDR1 +8 T>C†		MDR1 IVS1-81 del G‡		MSI-H§	
	Normal mucosa (n=14)	Tumour (n=14)	Normal mucosa (n=11)	Tumour (n=11)	Normal mucosa (n=17)	Tumour (n=17)	Normal mucosa (n=12)	Tumour (n=12)
Low	3 (21%)	1 (7%) (0,0,1)¶	3 (27%)	2 (18%) (0,1,1)¶	7 (41%)	2 (12%) (0,0,2)¶	4 (33%)	6 (50%) (0,0,6)¶
Moderate	4 (29%)	6 (43%) (1,5,0)	6 (55%)	4 (36%) (1,3,0)	7 (41%)	8 (47%) (2,6,0)	4 (33%)	1 (9%) (0,1,0)
High	7 (50%)	7 (50%) (3,4,0)	2 (18%)	5 (46%) (2,3,0)	3 (18%)	7 (41%) (3,4,0)	4 (33%)	5 (40%) (1,4,0)
All 54 (13,31,10)¶	14	14 (4,9,1)	11	11 (3,7,1)	17	17 (5,10,2)	12	12 (1,5,6)

\*Colorectal cancer (CRC) patients with microsatellite stable tumours and without germline functional *MDR1* polymorphisms were used as a control group.

†CRC patients with germline *MDR1* promoter polymorphism (+8T>C).

‡CRC patients with germline *MDR1* functional polymorphism in intron 1 (IVS81 delG).

§CRC patients with tumours exhibiting high microsatellite instability (MSI-H).

¶No of well differentiated tumours, No of moderately differentiated tumours, No of poorly differentiated tumours.

is the first report of naturally occurring somatic mutations in the *MDR1* gene in cancer patients, as previously only acquired mutations were reported in resistant tumours after chemotherapy.<sup>2</sup> Of the somatic coding mutations, there was one frameshift and two missense mutations changing amino acids conserved throughout species. Also, one unique germline mutation changed a conserved amino acid which results in changed polarity at this position (sample MSI 11, fig 2). Identified *MDR1* mutations in MSI-H tumours might change the functional activity of Pgp. The functional testing of these mutations in transfected cells is under way. In 4/5 MSI-H CRC with coding *MDR1* alterations, we identified concomitant alterations in the promoter region ( $p < 0.001$ ). Two MSI-H CRC (samples MSI 3 and MSI 5) had germline promoter mutation and somatic mutation in the coding region, sample MSI 11 had somatic mutation in the promoter and germline mutation in the coding region, and sample MSI 19 had two somatic mutations in the promoter and coding regions, respectively. Since it is unlikely that promoter and coding mutations would appear in the same tumours by chance, it is possible that *MDR1* mutations in these MSI-H tumours are selected during tumorigenesis. Interestingly, none of these MSI-H tumours had mutations in the coding regions of major mismatch repair genes as determined in our previous study.<sup>12</sup> Only 1/5 somatic *MDR1* mutations identified in MSI-H CRC in our study was a deletion of one adenine in the (A)<sub>n</sub> tract in exon 20 of the *MDR1* gene (2422-2426 del A, sample MSI 19), although inactivating frameshift mutations resulting from 1 bp deletions or 1 bp insertions in mononucleotide tracts of genes are usually found in MSI-H CRC. The missense mutations in the coding region of *MDR1* do not necessarily inactivate Pgp function, but could even increase Pgp functional transport activity<sup>2</sup> or could alternatively alter the substrate spectrum.<sup>16</sup> The high Pgp activity might protect intestinal cells against a wide variety of caspase dependent death stimuli, including FasL, tumour necrosis factor, and UV radiation<sup>5</sup> and therefore contribute to cancer progression. Pgp might be a downstream target of WNT signalling pathway, the most important pathway altered in colorectal cancers, as a transcription factor complex TCF4/ $\beta$  catenin responsive element was identified in the *MDR1* promoter region.<sup>10</sup> In addition to the role in tumour progression, *MDR1* mutations might also contribute to resistance to several chemotherapeutic agents often associated with MSI cancers.

We identified two polymorphisms, one in the promoter (+8 T>C,  $p = 0.036$ ) and one in intron 1 (IVS1-81delG,  $p = 0.010$ ), associated with lymphoid infiltration in tumours from CRC patients with or without MSI (table 2). CRC patients with these two polymorphisms tended to have lower Pgp expression in epithelial cells (table 3). In particular, the germline polymorphism in the promoter region might have an important influence on Pgp functional activity. We found the same polymorphism in two MSI-H CRC with concomitant

- In this study we provide a systematic analysis of naturally occurring germline and somatic alterations in the *MDR1* gene coding for P glycoprotein (Pgp) ABC transporter. The promoter and complete coding region of the *MDR1* gene was analysed in 400 patients with previously untreated colorectal cancer (CRC) and in a control normal population.
- We identified 12 different germline and five different somatic alterations. Two unique germline and all five somatic alterations were identified only in CRC patients exhibiting high microsatellite instability (MSI-H). In 4/5 MSI-H tumours with mutations in the coding region, there were concomitant mutations in the promoter region ( $p < 0.001$ ).
- We observed low Pgp expression in half of the MSI-H tumours mainly associated with poorly differentiated MSI-H tumours. We observed a significant increase (>80%) in methylation of CpG sites in the *MDR1* promoter in tumour DNA from 10/12 (80%) of MSI-H tumours.
- We also identified two germline *MDR1* polymorphisms associated with lymphoid infiltration, one in the promoter (+8 T>C,  $p = 0.036$ ) and one in intron 1 (IVS1-81delG,  $p = 0.010$ ) in both MSI-H and tumours without MSI. These two polymorphisms were associated with lower Pgp expression.
- These results suggest that the *MDR1* gene may be involved in initiation and progression of MSI-H tumours. Our results may also support the previously suggested role for Pgp in immune response.

somatic mutations in the coding region (samples MSI 3, MSI 5, table 1). However, 12 CRC samples with promoter polymorphism (+8 T>C) but without MSI were included in mutation screening of the complete *MDR1* coding region, but no additional mutations were found. Previously, this promoter polymorphism has been associated with haematological malignancies.<sup>17</sup> Our results might support the previously suggested role for Pgp in immune response.<sup>4, 18</sup>

Consistent with previous reports, we observed higher Pgp staining in tumour cells as compared to normal mucosa cells even in untreated tumours. Pgp expression was correlated with tumour differentiation. The lower Pgp expression we observed in MSI-H tumours might be associated with poor differentiation of MSI-H tumours and hypermethylation of the *MDR1* promoter. We found hypermethylation of the *MDR1* promoter in 10/12 (80%) MSI-H tumours, including 5/6 MSI-H tumours with *MDR1* mutations, but in none of the 10 MSS tumours and corresponding normal mucosa ( $p < 0.001$ ). Two MSI-H CRC samples (MSI 14 and MSI 22) that lack *MDR1* hypermethylation also lack *hMLH1* hypermethylation as we

determined in our previous study.<sup>12</sup> The other 10 MSI-H CRC analysed had methylation in both genes *MDR1* and *hMLH1*, suggesting the more general failure of correct methylating mechanism in these tumours.

In conclusion, we identified germline and somatic mutations in the *MDR1* gene associated with MSI-H tumours suggesting a role of *MDR1* in progression of at least a subgroup of MSI-H tumours. Finding of novel genes mutated in MSI-H CRC might help in the understanding of tumorigenesis and to design appropriate treatment. The characterisation of naturally occurring functional polymorphisms and mutations in the *MDR1* gene could also provide a good basis for functional studies of Pgp.

## ACKNOWLEDGEMENTS

The Ministry of Education, Science, and Sport of the Republic of Slovenia supported this study (Project J3-7919-0381). The scope of the study was agreed by the Medical Ethical Commission of the Republic of Slovenia in October 1995. We are grateful to patients who participated in the study. We thank Rastko Golouh and Stanislav Repše for patient tissue samples. We thank Anton Cerar for help with the evaluation of immunohistochemistry results. We also thank Teo Zizek and Aleš Novak for excellent technical assistance and Matej Bracko for statistical calculations.

.....

## Authors' affiliations

**U Potočnik, M Ravnik-Glavač, D Glavač**, Laboratory of Molecular Genetics, Institute of Pathology, Medical Faculty, Ljubljana, Slovenia  
**M Ravnik-Glavač**, Institute of Biochemistry, Medical Faculty, Ljubljana, Slovenia  
**R Golouh**, Department of Pathology, Institute of Oncology, Ljubljana, Slovenia

Correspondence to: Dr D Glavač, University of Ljubljana, Medical Faculty, Institute of Pathology, Laboratory of Molecular Genetics, Korytkova 2, 1000 Ljubljana, Slovenia; damjan.glavac@mf.uni-lj.si

## REFERENCES

- 1 Ueda K, Cardarelli C, Gottesman MM, Pastan I. Expression of a full-length cDNA for the human "MDR1" gene confers resistance to colchicine, doxorubicin, and vinblastine. *Proc Natl Acad Sci USA* 1987;**84**:3004-8.
- 2 Choi KH, Chen CJ, Kriegler M, Roninson IB. An altered pattern of cross-resistance in multidrug-resistant human cells results from spontaneous mutations in the *mdr1* (P-glycoprotein) gene. *Cell* 1988;**53**:519-29.
- 3 Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. *Proc Natl Acad Sci USA* 1987;**84**:7735-8.
- 4 Randolph GJ, Beaulieu S, Pope M, Sugawara I, Hoffman L, Steinman RM, Muller WA. A physiologic function for p-glycoprotein (MDR-1) during the migration of dendritic cells from skin via afferent lymphatic vessels. *Proc Natl Acad Sci USA* 1998;**95**:6924-9.
- 5 Johnstone RW, Cretney E, Smyth MJ. P-glycoprotein protects leukemia cells against caspase-dependent, but not caspase-independent, cell death. *Blood* 1999;**93**:1075-85.
- 6 Fojo AT, Ueda K, Slamon DJ, Poplack DG, Gottesman MM, Pastan I. Expression of a multidrug-resistance gene in human tumors and tissues. *Proc Natl Acad Sci USA* 1987;**84**:265-9.
- 7 Weinstein RS, Jakate SM, Dominguez JM, Lebovitz MD, Koukoulis GK, Kuzak JR, Klusens LF, Grogan TM, Saclarides TJ, Roninson JB, Coon JS. Relationship of the expression of the multidrug resistance gene product (P-glycoprotein) in human colon carcinoma to local tumor aggressiveness and lymph node metastasis. *Cancer Res* 1991;**51**:2720-6.
- 8 Lynch HT, de la Chapelle A. Genetic susceptibility to non-polyposis colorectal cancer. *J Med Genet* 1999;**36**:801-18.
- 9 Aebi S, Kurdi-Haidar B, Gordon R, Cenni B, Zheng H, Fink D, Christen RD, Boland CR, Koi M, Fishel R, Howell SB. Loss of DNA mismatch repair in acquired resistance to cisplatin. *Cancer Res* 1996;**56**:3087-90.
- 10 Yamada T, Takaoka AS, Naishiro Y, Hayashi R, Maruyama K, Maesawa C, Ochiai A, Hirohashi S. Transactivation of the multidrug resistance 1 gene by T-cell factor 4/beta-catenin complex in early colorectal carcinogenesis. *Cancer Res* 2000;**60**:4761-6.
- 11 Jass JR, Atkin WS, Cuzick J, Bussey HJ, Morson BC, Northover JM, Todd IP. The grading of rectal cancer: historical perspectives and a multivariate analysis of 447 cases. *Histopathology* 1986;**10**:437-59.
- 12 Potocnik U, Glavac D, Golouh R, Ravnik-Glavac M. Causes of microsatellite instability in colorectal tumors: implications for hereditary non-polyposis colorectal cancer screening. *Cancer Genet Cytogenet* 2001;**126**:85-96.
- 13 Ravnik-Glavac M, Glavac D, Dean M. Sensitivity of single-strand conformation polymorphism and heteroduplex method for mutation detection in the cystic fibrosis gene. *Hum Mol Genet* 1994;**3**:801-7.
- 14 Raizis AM, Schmitt F, Jost JP. A bisulfite method of 5-methylcytosine mapping that minimizes template degradation. *Anal Biochem* 1995;**226**:161-6.
- 15 Fryxell KB, McGee SB, Simoneaux DK, Willman CL, Cornwell MM. Methylation analysis of the human multidrug resistance 1 gene in normal and leukemic hematopoietic cells. *Leukemia* 1999;**13**:910-17.
- 16 Gottesman MM, Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. *Annu Rev Biochem* 1993;**62**:385-427.
- 17 Rund D, Azar I, Shperling O. A mutation in the promoter of the multidrug resistance gene (MDR1) in human hematological malignancies may contribute to the pathogenesis of resistant disease. *Adv Exp Med Biol* 1999;**5**:71-5.
- 18 Panwala CM, Jones JC, Viney JL. A novel model of inflammatory bowel disease: mice deficient for the multiple drug resistance gene, *mdr1a*, spontaneously develop colitis. *J Immunol* 1998;**161**:5733-44.
- 19 Kohno K, Sato S, Uchiyama T, Takano H, Kato S, Kuwano M. Tissue-specific enhancer of the human multidrug-resistance (MDR1) gene. *J Biol Chem* 1990;**265**:19690-6.
- 20 Stein U, Walther W, Wunderlich V. Point mutations in the *mdr1* promoter of human osteosarcomas are associated with in vitro responsiveness to multidrug resistance relevant drugs. *Eur J Cancer* 1994;**30**:1541-5.
- 21 Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmoller J, Johnhe A, Cascorbi I, Gerloff T, Roots I, Eichelbaum M, Brinkmann U. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. *Proc Natl Acad Sci USA* 2000;**97**:3473-8.
- 22 Mickley LA, Lee JS, Weng Z, Zhan Z, Alvarez M, Wilson W, Bates SE, Fojo T. Genetic polymorphism in MDR-1: a tool for examining allelic expression in normal cells, unselected and drug-selected cell lines, and human tumors. *Blood* 1998;**91**:1749-56.